Gene editing and clonal isolation of human induced pluripotent stem cells using CRISPR/Cas9

Methods

Volumn 121-122, Issue , 2017, Pages 29-44

  Yumlu, Saniye ^a,b   Stumm, Jürgen ^a,c   Bashir, Sanum ^a,b   Dreyer, Anne Kathrin ^a,b   Lisowski, Pawel ^a,d   Danner, Eric ^a   Kühn, Ralf ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b BERLIN INSTITUTE OF HEALTH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d INSTITUTE OF GENETICS AND ANIMAL BREEDING   (Poland)

Author keywords

Cas9; CRISPR; Gene editing; Knockin; Knockout; Pluripotent stem cells

Indexed keywords

RNA; BACTERIAL PROTEIN; CAS9 ENDONUCLEASE STREPTOCOCCUS PYOGENES; DNA; DOXYCYCLINE; ENDONUCLEASE; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; GUIDE RNA; LIPID; LIPOFECTAMINE;

ARTICLE; CELL CLONE; CELL ISOLATION; CONTROLLED STUDY; CRISPR CAS SYSTEM; EXPRESSION VECTOR; FLUORESCENCE ACTIVATED CELL SORTING; GENE AMPLIFICATION; GENE EDITING; GENE LOCUS; GENETIC TRANSFECTION; GENOTYPE; HUMAN; HUMAN CELL; INDUCED PLURIPOTENT STEM CELL; MOLECULAR CLONING; PLASMID; PRIORITY JOURNAL; REPORTER GENE; STEM CELL CULTURE; CELL LINE; CHEMISTRY; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CYTOLOGY; DRUG EFFECTS; ELECTROPORATION; FLOW CYTOMETRY; GENE TARGETING; GENE TRANSFER; GENETICS; HUMAN GENOME; METABOLISM; PROCEDURES;

BACTERIAL PROTEINS; CELL LINE; CLONE CELLS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-CAS SYSTEMS; DNA; DOXYCYCLINE; ELECTROPORATION; ENDONUCLEASES; FLOW CYTOMETRY; GENE EDITING; GENE TARGETING; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENOME, HUMAN; GREEN FLUORESCENT PROTEINS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LIPIDS; PLASMIDS; RNA, GUIDE;

EID: 85020198485     PISSN: 10462023     EISSN: 10959130     Source Type: Journal    
DOI: 10.1016/j.ymeth.2017.05.009     Document Type: Article

References (48)

1. Takahashi, K., Yamanaka, S., Induced pluripotent stem cells in medicine and biology. Development 140 (2013), 2457–2461, 10.1242/dev.092551.
2. Sterneckert, J.L., Reinhardt, P., Scholer, H.R., Investigating human disease using stem cell models. Nat. Rev. Genet. 15 (2014), 625–639, 10.1038/nrg3764.
3. Takahashi, K., Yamanaka, S., A decade of transcription factor-mediated reprogramming to pluripotency. Nat. Rev. Mol. Cell Biol. 17 (2016), 183–193, 10.1038/nrm.2016.8.
4. Tao, Y., Zhang, S.-C., Neural subtype specification from human pluripotent stem cells. Cell Stem Cell. 19 (2016), 573–586, 10.1016/j.stem.2016.10.015.
5. Priori, S.G., Napolitano, C., Di Pasquale, E., Condorelli, G., Induced pluripotent stem cell–derived cardiomyocytes in studies of inherited arrhythmias. J. Clin. Invest. 123 (2013), 84–91, 10.1172/JCI62838.
6. Hockemeyer, D., Jaenisch, R., Induced pluripotent stem cells meet genome editing. Cell Stem Cell. 18 (2016), 573–586, 10.1016/j.stem.2016.04.013.
7. Hotta, A., Yamanaka, S., From genomics to gene therapy: induced pluripotent stem cells meet genome editing. Annu. Rev. Genet. 49 (2015), 47–70, 10.1146/annurev-genet-112414-054926.
8. Zuk, O., Hechter, E., Sunyaev, S.R., Lander, E.S., The mystery of missing heritability: Genetic interactions create phantom heritability. Proc. Natl. Acad. Sci. 109 (2012), 1193–1198, 10.1073/pnas.1119675109.
9. Lehner, B., Molecular mechanisms of epistasis within and between genes. Trends Genet. 27 (2011), 323–331, 10.1016/j.tig.2011.05.007.
10. Sternberg, S.H., Doudna, J.A., Expanding the Biologist's Toolkit with CRISPR-Cas9. Mol. Cell. 58 (2015), 568–574, 10.1016/j.molcel.2015.02.032.
11. Ding, Q., Regan, S.N., Xia, Y., Oostrom, L.A., Cowan, C.A., Musunuru, K., Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell. 12 (2013), 393–394, 10.1016/j.stem.2013.03.006.
12. Kim, H.S., Bernitz, J.M., Lee, D.-F., Lemischka, I.R., Genomic Editing Tools to Model Human Diseases with Isogenic Pluripotent Stem Cells. Stem Cells Dev. 23 (2014), 2673–2686, 10.1089/scd.2014.0167.
13. Hendriks, W.T., Warren, C.R., Cowan, C.A., Genome editing in human pluripotent stem cells: approaches. Pitfalls, and Solutions, Cell Stem Cell. 18 (2016), 53–65, 10.1016/j.stem.2015.12.002.
14. Ran, F.A., Hsu, P.P.D., Wright, J., Agarwala, V., Scott, D.A., Zhang, F., Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8 (2013), 2281–2308, 10.1038/nprot.2013.143.
15. Lieber, M.R., The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu. Rev. Biochem. 79 (2010), 181–211, 10.1146/annurev.biochem.052308.093131.
16. San Filippo, J., Sung, P., Klein, H., Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 77 (2008), 229–257, 10.1146/annurev.biochem.77.061306.125255.
17. Heyer, W.-D., Ehmsen, K.T., Liu, J., Regulation of Homologous Recombination in Eukaryotes. Annu. Rev. Genet. 44 (2010), 113–139, 10.1146/annurev-genet-051710-150955.
18. Sorrell, D.A., Kolb, A.F., Targeted modification of mammalian genomes. Biotechnol. Adv. 23 (2005), 431–469, 10.1016/j.biotechadv.2005.03.003.
19. González, F., Zhu, Z., Shi, Z.D., Lelli, K., Verma, N., Li, Q.V., Huangfu, D., An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell. 15 (2014), 215–226, 10.1016/j.stem.2014.05.018.
20. Park, C.-Y., Kim, J., Kweon, J., Son, J.S., Lee, J.S., Yoo, J.-E., Cho, S.-R., Kim, J.-H., Kim, J.-S., Kim, D.-W., Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs. Proc. Natl. Acad. Sci. 111 (2014), 9253–9258, 10.1073/pnas.1323941111.
21. Turan, S., Farruggio, A.P., Srifa, W., Day, J.W., Calos, M.P., Precise correction of disease mutations in induced pluripotent stem cells derived from patients with limb girdle muscular dystrophy. Mol. Ther. 24 (2016), 685–696, 10.1038/mt.2016.40.
22. Ye, L., Wang, J., Beyer, A.I., Teque, F., Cradick, T.J., Qi, Z., Chang, J.C., Bao, G., Muench, M.O., Yu, J., Levy, J.A., Kan, Y.W., Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc. Natl. Acad. Sci. 111 (2014), 9591–9596, 10.1073/pnas.1407473111.
23. Merkle, F.T., Neuhausser, W.M., Santos, D., Valen, E., Gagnon, J.A., Maas, K., Sandoe, J., Schier, A.F., Eggan, K., Efficient CRISPR-Cas9-mediated generation of knockin human pluripotent stem cells lacking undesired mutations at the targeted locus. Cell Rep. 11 (2015), 875–883, 10.1016/j.celrep.2015.04.007.
24. Paquet, D., Kwart, D., Chen, A., Sproul, A., Jacob, S., Teo, S., Olsen, K.M., Gregg, A., Noggle, S., Tessier-Lavigne, M., Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature. 533 (2016), 125–129, 10.1038/nature17664.
25. Shin, J.W., Kim, K.-H., Chao, M.J., Atwal, R.S., Gillis, T., MacDonald, M.E., Gusella, J.F., Lee, J.-M., Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9. Hum. Mol. Genet., 2016, ddw286, 10.1093/hmg/ddw286.
26. Tsai, S.Q., Joung, J.K., Defining and improving the genome-wide specificities of CRISPR–Cas9 nucleases. Nat. Rev. Genet. 17 (2016), 300–312, 10.1038/nrg.2016.28.
27. Veres, A., Gosis, B.S., Ding, Q., Collins, R., Ragavendran, A., Brand, H., Erdin, S., Cowan, C.A., Talkowski, M.E., Musunuru, K., Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell. 15 (2014), 27–30, 10.1016/j.stem.2014.04.020.
28. Suzuki, K., Yu, C., Qu, J., Li, M., Yao, X., Yuan, T., Goebl, A., Tang, S., Ren, R., Aizawa, E., Zhang, F., Xu, X., Soligalla, R.D., Chen, F., Kim, J., Kim, N.Y., Liao, H.-K., Benner, C., Esteban, C.R., Jin, Y., Liu, G.-H., Li, Y., Izpisua Belmonte, J.C., Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. Cell Stem Cell. 15 (2014), 31–36, 10.1016/j.stem.2014.06.016.
29. Yang, L., Grishin, D., Wang, G., Aach, J., Zhang, C.-Z., Chari, R., Homsy, J., Cai, X., Zhao, Y., Fan, J.-B., Seidman, C., Seidman, J., Pu, W., Church, G., Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells. Nat. Commun., 5, 2014, 5507, 10.1038/ncomms6507.
30. Slaymaker, I.M., Gao, L., Zetsche, B., Scott, D.A., Yan, W.X., Zhang, F., Rationally engineered Cas9 nucleases with improved specificity. Science (80-.) 351 (2016), 84–88, 10.1126/science.aad5227.
31. Kleinstiver, B.P., Pattanayak, V., Prew, M.S., Tsai, S.Q., Nguyen, N.T., Zheng, Z., Keith Joung, J., High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529 (2016), 490–495, 10.1038/nature16526.
32. Streeter, I., Harrison, P.W., Faulconbridge, A., Flicek, P., Parkinson, H., Clarke, L., The human-induced pluripotent stem cell initiative—data resources for cellular genetics. Nucleic Acids Res. 45 (2017), D691–D697, 10.1093/nar/gkw928.
33. Xi, L., Schmidt, J.C., Zaug, A.J., Ascarrunz, D.R., Cech, T.R., A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression. Genome Biol., 16, 2015, 231, 10.1186/s13059-015-0791-1.
34. Schick, J.A., Seisenberger, C., Beig, J., Bürger, A., Iyer, V., Maier, V., Perera, S., Rosen, B., Skarnes, W.C., Wurst, W., CRISPR-Cas9 enables conditional mutagenesis of challenging loci. Sci. Rep., 6, 2016, 32326, 10.1038/srep32326.
35. Miyaoka, Y., Chan, A.H., Judge, L.M., Yoo, J., Huang, M., Nguyen, T.D., Lizarraga, P.P., So, P.-L., Conklin, B.R., Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat. Methods 11 (2014), 291–293, 10.1038/nmeth.2840.
36. Makino, S., Fukumura, R., Gondo, Y., Illegitimate translation causes unexpected gene expression from on-target out-of-frame alleles created by CRISPR-Cas9. Sci. Rep., 6, 2016, 39608, 10.1038/srep39608.
37. Pedersen, A.G., Nielsen, H., Neural network prediction of translation initiation sites in eukaryotes: perspectives for EST and genome analysis. Proc. Int. Conf. Intell. Syst. Mol. Biol. 5 (1997), 226–233.
38. Park, C.-Y., Sung, J.J., Choi, S.-H., Lee, D.R., Park, I.-H., Kim, D.-W., Modeling and correction of structural variations in patient-derived iPSCs using CRISPR/Cas9. Nat. Protoc. 11 (2016), 2154–2169, 10.1038/nprot.2016.129.
39. Kraft, K., Geuer, S., Will, A.J., Chan, W.L., Paliou, C., Borschiwer, M., Harabula, I., Wittler, L., Franke, M., Ibrahim, D.M., Kragesteen, B.K., Spielmann, M., Mundlos, S., Lupiáñez, D.G., Andrey, G., Deletions inversions, duplications: engineering of structural variants using CRISPR/Cas in mice. Cell Rep. 10 (2015), 833–839, 10.1016/j.celrep.2015.01.016.
40. Haeussler, M., Schönig, K., Eckert, H., Eschstruth, A., Mianné, J., Renaud, J.-B., Schneider-Maunoury, S., Shkumatava, A., Teboul, L., Kent, J., Joly, J.-S., Concordet, J.-P., Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol., 17, 2016, 148, 10.1186/s13059-016-1012-2.
41. Yang, L., Guell, M., Byrne, S., Yang, J.L., De Los Angeles, A., Mali, P., Aach, J., Kim-Kiselak, C., Briggs, A.W., Rios, X., Huang, P.Y., Daley, G., Church, G., Optimization of scarless human stem cell genome editing. Nucleic Acids Res. 41 (2013), 9049–9061, 10.1093/nar/gkt555.
42. Richardson, C.D., Ray, G.J., DeWitt, M.A., Curie, G.L., Corn, J.E., Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat. Biotechnol. 34 (2016), 339–344, 10.1038/nbt.3481.
43. Renaud, J.B., Boix, C., Charpentier, M., De Cian, A., Cochennec, J., Duvernois-Berthet, E., Perrouault, L., Tesson, L., Edouard, J., Thinard, R., Cherifi, Y., Menoret, S., Fontanière, S., de Crozé, N., Fraichard, A., Sohm, F., Anegon, I., Concordet, J.P., Giovannangeli, C., Improved genome editing efficiency and flexibility using modified oligonucleotides with TALEN and CRISPR-Cas9 nucleases. Cell Rep. 14 (2016), 2263–2272, 10.1016/j.celrep.2016.02.018.
44. Glaser, A., McColl, B., Vadolas, J., GFP to BFP conversion: a versatile assay for the quantification of CRISPR/Cas9-mediated genome editing. Mol. Ther. Acids., 5, 2016, e334, 10.1038/mtna.2016.48.
45. Hasty, P., Abuin, A., Bradley, A., Gene targeting, principles, and practice in mammalian cells. Joyner, A., (eds.) Gene Target. A Pract. Approach, second ed., 2000, Oxford University Press, Oxford, 1–35.
46. Wefers, B., Wurst, W., Kühn, R., Design and Generation of Gene-Targeting Vectors. Curr. Protoc. Mouse Biol., 2011, John Wiley & Sons, Inc., Hoboken, NJ, USA, 199–211, 10.1002/9780470942390.mo100179.
47. Derek Peters, Chad Cowan, Kiran Musunuru, Genome editing in human pluripotent stem cells, in: StemBook, Cambridge, 2014. doi:10.3824/stembook.1.94.1.
48. Brinkman, E.K., Chen, T., Amendola, M., van Steensel, B., Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res., 42, 2014, e168, 10.1093/nar/gku936.